Table of contents
September 2006 Vol 6 No 9
From the editors
p653 | doi:10.1038/nrc1990
Research Highlights
Targeted therapy: Stressed out hearts
p655 | doi:10.1038/nrc1980
Tumorigenesis: Decidedly different
p656 | doi:10.1038/nrc1981
In the news
In the news
p656 | doi:10.1038/nrc1987
Anticancer agents: Digging in
p657 | doi:10.1038/nrc1960
Tumour transmission: Transmission possible
p657 | doi:10.1038/nrc1983
Metastasis: Anger management
p658 | doi:10.1038/nrc1985
Tumorigenesis: Stress and cancer
p658 | doi:10.1038/nrc1986
Targeted therapies: The next move
p659 | doi:10.1038/nrc1988
Signalling: Eph-ective tumour growth inhibition
p660 | doi:10.1038/nrc1978
Pharmacodynamics: A new model
p660 | doi:10.1038/nrc1982
Therapy: Through the barricades
p660 | doi:10.1038/nrc1984
In brief
Angiogenesis | Tumour suppressors | Metastasis | Cell death
p661 | doi:10.1038/nrc1989
Reviews
Divorcing ARF and p53: an unsettled case
Charles J. Sherr
p663 | doi:10.1038/nrc1954
The ARF tumour suppressor can activate p53-dependent transcriptional pathways by inhibiting the ubiquitin ligase MDM2. However, ARF has been reported to have p53-independent activities. How important are these activities in tumorigenesis? This Review critically appraises the current data.
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi & Ronald A. DePinho
p674 | doi:10.1038/nrc1934
Hepatocellular carcinoma (HCC) is highly lethal and has a high incidence worldwide. However, at present there is only a basic understanding of the genetic, cellular and environmental mechanisms that drive HCC pathogenesis. What is known, and what are the challenges and opportunities?
Polymer conjugates as anticancer nanomedicines
Ruth Duncan
p688 | doi:10.1038/nrc1958
Polymers can be conjugated to anticancer drugs and proteins to improve their therapeutic index. Some such conjugates are in routine clinical use and there are exciting advances in development, such as polymer-based combination therapies.
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
Søren M. Bentzen
p702 | doi:10.1038/nrc1950
Progress in molecular radiobiology has improved the understanding of the pathogenesis of side effects that develop months or years after radiotherapy has been completed. This knowledge will help to improve the therapeutic efficacy of radiotherapy and the quality of life of long-term cancer survivors.
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai & Akinori Takaoka
p714 | doi:10.1038/nrc1913
Several small-molecule inhibitors and monoclonal antibodies are now approved for the therapy of various cancers. Focusing on the example of the epidermal growth factor receptor inhibitors, this Review compares and contrasts these two classes of agents.
Perspectives
Opinion
mTOR and cancer: insights into a complex relationship
David M. Sabatini
p729 | doi:10.1038/nrc1974
Drugs that target mTOR (mammalian target of rapamycin) have entered clinical trials for cancer treatment. However, current mTOR inhibitors have an unexpectedly complex mechanism of action. Can our emerging knowledge of this pathway be used to develop more effective mTOR-targeted therapies?
Opinion
Linking oncogenic pathways with therapeutic opportunities
Andrea H. Bild, Anil Potti & Joseph R. Nevins
p735 | doi:10.1038/nrc1976
Multiple mutations and alterations in the cancer genome lead to the deregulation of various cell-signalling pathways that control cell function. Can molecular-profiling studies be used to fully understand this complexity and provide an opportunity to link pathway deregulation with potential therapeutic strategies?
Corrigendum: Drug interactions in cancer therapy
Charity D. Scripture & William D. Figg
p741 | doi:10.1038/nrc1975
Erratum: Lineage dependency and lineage-survival oncogenes in human cancer
Levi A. Garraway & William R. Sellers
p742 | doi:10.1038/nrc1972
Erratum: Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Alexander J. Muller & Peggy A. Scherle
p742 | doi:10.1038/nrc1979